Ascendis Pharma Files 6-K with Q1 2025 Financials
Ticker: ASND · Form: 6-K · Filed: May 1, 2025 · CIK: 1612042
Sentiment: neutral
Topics: financials, 6-K, reporting
TL;DR
Ascendis Pharma dropped Q1 2025 financials, showing balance sheet details.
AI Summary
Ascendis Pharma A/S filed a 6-K report on May 1, 2025, for the period ending March 31, 2025. The filing includes financial information such as share premium and retained earnings as of March 31, 2025, and December 31, 2024. It also references convertible senior notes and American Depository Shares.
Why It Matters
This filing provides investors with an update on Ascendis Pharma's financial position and key balance sheet items as of the end of the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) that provides standard financial reporting and does not indicate any unusual events or significant changes.
Key Numbers
- Q1 2025 — Reporting Period (Financials are reported as of March 31, 2025.)
- 2024-12-31 — Prior Year End (Comparison point for financial data.)
Key Players & Entities
- Ascendis Pharma A/S (company) — Filer of the report
- 0000950170-25-061850 (filing_id) — Accession number for the filing
- 20250331 (date) — Reporting period end date
- 20250501 (date) — Filing date
FAQ
What specific financial liabilities are detailed in the filing?
The filing references 'FinancialLiabilitiesAtFairValueMember' and 'FinancialLiabilitiesAtAmortisedCostMember' as of March 31, 2025.
What is the fiscal year end for Ascendis Pharma A/S?
The fiscal year end for Ascendis Pharma A/S is December 31.
What types of equity are mentioned in the filing?
The filing mentions 'SharePremiumMember' and 'RetainedEarningsMember' as of March 31, 2025, and 'TreasurySharesMember' as of March 31, 2024.
What is the SEC file number for Ascendis Pharma A/S?
The SEC file number for Ascendis Pharma A/S is 001-36815.
What is the business address of Ascendis Pharma A/S?
The business address is Tuborg Boulevard 12, Hellerup, DK-2900.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 1, 2025 regarding Ascendis Pharma A/S (ASND).